c19early.org COVID-19 treatment researchCOVID-19 treatments

Real World Outcomes of Cancer Patients With SARS-CoV-2 Infection Receiving Monoclonal Antibodies

Wilden et al., Journal of the National Comprehensive Cancer Network, doi:10.6004/jnccn.2021.7309, Mar 2022

Bamlanivimab/etesevimab for COVID-19

24th treatment shown to reduce risk in May 2021, now with p = 0.00049 from 22 studies, recognized in 11 countries. Efficacy is variant dependent.
Lower risk for mortality, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective.
Protocols combine treatments.

6,700+ studies · 220+ treatments

c19early.org
Meta-analysis
Retrospective 395 patients in the USA receiving casirivimab/imdevimab or bamlanivimab, showing lower risk of hospitalization with treatment, statistically significant for casirivimab/imdevimab.
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron1-5.
Although the 51% lower hospitalization is not statistically significant, it is consistent with the significant 42% lower hospitalization [30‑53%] from meta-analysis of the 15 hospitalization results to date.
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments6. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
Important missing comments or errors? Let us know.
Study covers bamlanivimab/etesevimab and casirivimab/imdevimab.
OutcomeImprovementEffect · pTreatmentControl
risk of hospitalization 51.0% lower · OR 0.49 · p = 0.06 51.0% lowerOR 0.49p = 0.06 , adjusted per studyRR approximated with ORmultivariable

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates.

Wilden et al., 31 Mar 2022, retrospective, USA, peer-reviewed, 9 authors, study period December 2020 - July 2021.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Jordan Georgia Switzerland Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Jordan Georgia Switzerland Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
DOI record: { "DOI": "10.6004/jnccn.2021.7309", "ISSN": [ "1540-1405", "1540-1413" ], "URL": "http://dx.doi.org/10.6004/jnccn.2021.7309", "author": [ { "affiliation": [ { "name": "1 UT Southwestern Medical Center, Dallas, TX" } ], "family": "Wilden", "given": "Alexa", "sequence": "first" }, { "affiliation": [ { "name": "1 UT Southwestern Medical Center, Dallas, TX" } ], "family": "Sannareddy", "given": "Aishwarya", "sequence": "additional" }, { "affiliation": [ { "name": "1 UT Southwestern Medical Center, Dallas, TX" } ], "family": "Patel", "given": "Hetal", "sequence": "additional" }, { "affiliation": [ { "name": "1 UT Southwestern Medical Center, Dallas, TX" } ], "family": "Kansagra", "given": "Shraddha", "sequence": "additional" }, { "affiliation": [ { "name": "1 UT Southwestern Medical Center, Dallas, TX" } ], "family": "Kaur", "given": "Gurbakhash", "sequence": "additional" }, { "affiliation": [ { "name": "1 UT Southwestern Medical Center, Dallas, TX" } ], "family": "Ramakrishnan", "given": "Praveen", "sequence": "additional" }, { "affiliation": [ { "name": "1 UT Southwestern Medical Center, Dallas, TX" } ], "family": "Patel", "given": "Prapti", "sequence": "additional" }, { "affiliation": [ { "name": "2 Jacobi Medical Center, Bronx, NY" } ], "family": "Mehta", "given": "Ansh", "sequence": "additional" }, { "affiliation": [ { "name": "1 UT Southwestern Medical Center, Dallas, TX" } ], "family": "Kansagra", "given": "Ankit", "sequence": "additional" } ], "container-title": [ "Journal of the National Comprehensive Cancer Network" ], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2022, 3, 31 ] ], "date-time": "2022-03-31T11:49:36Z", "timestamp": 1648727376000 }, "deposited": { "date-parts": [ [ 2022, 3, 31 ] ], "date-time": "2022-03-31T11:50:05Z", "timestamp": 1648727405000 }, "indexed": { "date-parts": [ [ 2022, 4, 4 ] ], "date-time": "2022-04-04T00:56:40Z", "timestamp": 1649033800757 }, "is-referenced-by-count": 0, "issn-type": [ { "type": "print", "value": "1540-1405" }, { "type": "electronic", "value": "1540-1413" } ], "issue": "3.5", "issued": { "date-parts": [ [ 2022, 3, 31 ] ] }, "journal-issue": { "issue": "3.5" }, "link": [ { "URL": "https://jnccn.org/view/journals/jnccn/20/3.5/article-pHSR22-178.xml", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://jnccn.org/view/journals/jnccn/20/3.5/article-pHSR22-178.xml", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "4047", "original-title": [], "page": "HSR22-178", "prefix": "10.6004", "published": { "date-parts": [ [ 2022, 3, 31 ] ] }, "published-print": { "date-parts": [ [ 2022, 3, 31 ] ] }, "publisher": "Harborside Press, LLC", "reference-count": 0, "references-count": 0, "relation": {}, "resource": { "primary": { "URL": "https://jnccn.org/view/journals/jnccn/20/3.5/article-pHSR22-178.xml" } }, "score": 1, "short-container-title": [], "short-title": [], "source": "Crossref", "subject": [ "Oncology" ], "subtitle": [], "title": [ "HSR22-178: Real World Outcomes of Cancer Patients With SARS-CoV-2 Infection Receiving Monoclonal Antibodies" ], "type": "journal-article", "volume": "20" }